Medication Deprescribing: Views among Older Americans

Prioritizing Blood-Based CRC Tests May Lead to Higher Costs and Worse Outcomes, Study Finds

News

Slideshow

New survey of older adults shows the majority are open to stopping at least 1 of their medications—but some who already did so didn't consult their clinician first.

Medication deprescribing is a collaborative effort between patients and their health care provider to intentionally reduce or stop prescription medications, over-the-counter medications, and/or dietary supplements. What do patients think about medication deprescribing? The University of Michigan National Poll on Health Aging recently asked a national sample of older adults aged 50-80 years (n=2563) about their current medication use and experiences with deprescribing. In the slides below, find an overview of key findings.

Related Content

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

Keith A. Reynolds

October 1st 2024

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

October 25th 2023

DEA Amends Telehealth Prescribing Rules, Including Special Registration for Schedule II-V Medications

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Austin Littrell

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.

Patient Care Staff

Prioritizing Blood-Based CRC Tests May Lead to Higher Costs and Worse Outcomes, Study Finds

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Related Content

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

Keith A. Reynolds

October 1st 2024

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

October 25th 2023

DEA Amends Telehealth Prescribing Rules, Including Special Registration for Schedule II-V Medications

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Austin Littrell

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.

Patient Care Staff